Table 3.
L5 Trabecular Parameters: Anabolic Therapies
| Group | L5 Tb.N | L5 Tb.Th | L5 Tb.Sp | |||
|---|---|---|---|---|---|---|
| VEH: WT/Nmp4−/− | 3.71 ± 0.21/3.79 ± 0.15 | 0.051 ± 0.003/0.054 ± 0.003 | 0.250 ± 0.013/0.239 ± 0.017 | |||
| PTH: WT/Nmp4−/− | 5.82 ± 0.64/6.26 ± 0.49 | 0.047 ± 0.002/0.054 ± 0.002 | 0.191 ± 0.020/0.182 ± 0.021 | |||
| PTH+ALN: WT/Nmp4−/− | 6.24 ± 0.93/6.49 ± 0.62 | 0.049 ± 0.002/0.053 ± 0.003 | 0.188 ± 0.025/0.170 ± 0.017 | |||
| PTH+ZOL: WT/Nmp4−/− | 8.24 ± 0.1.87/9.0 ± 0.85 | 0.053 ± 0.003/0.057 ± 0.002 | 0.156 ± 0.044/0.135 ± 0.023 | |||
| PTH+RAL: WT/Nmp4−/− | 7.79 ± 0.65/8.05 ± 0.81 | 0.052 ± 0.002/0.061 ± 0.002 | 0.172 ± 0.003/0.159 ± 0.027 | |||
| Anabolic therapy | G: | P = 0.0483 | G: | P < 0.0001 | G: | P = 0.0091 |
| T: | P < 0.0001 | T: | P < 0.0001 | T: | P < 0.0001 | |
| PTH+ZOL | A | GxT: | P = 0.0010 | VEH | A | |
| PTH+RAL | A | Nmp4−/− PTH+RAL | A | PTH | B | |
| PTH+ALN | B | Nmp4−/− PTH+ZOL | B | PTH+ALN | B | |
| WT PTH | B | Nmp4−/− PTH | BC | PTH+RAL | BC | |
| VEH | C | Nmp4−/− VEH | BCD | PTH+ZOL | C | |
| GxT: | P = 0.76 | WT PTH+ZOL | CD | GxT: | P = 0.94 | |
| Nmp4−/− PTH+ALN | CD | |||||
| WT PTH+RAL | CD | |||||
| WT VEH | DE | |||||
| WT PTH+ALN | EF | |||||
| WT PTH | F | |||||
The micro-CT analyses of the L5 trabecular architecture in mice treated with the anabolic therapies. The data were analyzed using two-way analyses of variance comparing the anabolic therapies and the anticatabolic monotherapies. Statistical significance was set at P ≤ 0.05, and levels not connected by the same letter are significantly different. The data represent mean ± standard deviation, n = 7 to 12 mice per group.
Abbreviations: G, genotype; T, treatment.